



Basic Annual Drug List Updates

April 2021

| TRADE NAME (generic name) | Brand/Generic Product | Description of Change |
|---|------------------------------|------------------------------|
| EPCLUSA (sofosbuvir-velpatasvir tab 200-50 mg) | Brand | Addition, Preferred Status |
| RETACRIT (epoetin alfa-epbx inj 20000 unit/ml) | Brand | Addition, Preferred Status |
| RETEVMO (selpercatinib cap 40 mg) | Brand | Addition, Preferred Status |
| RETEVMO (selpercatinib cap 80 mg) | Brand | Addition, Preferred Status |
| SYMTUZA (darunavir-cobic-emtricitab-tenofov af tab 800-150-200-10 mg) | Brand | Addition, Preferred Status |
| TAKHZYRO (lanadelumab-flyo inj 300 mg/2ml (150 mg/ml)) | Brand | Addition, Preferred Status |

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent Licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Illinois (BCBSIL) contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.